Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Research & Development (2016 - 2025)

Altimmune (ALT) has disclosed Research & Development for 16 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 6.94% to $18.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.4 million through Dec 2025, down 19.21% year-over-year, with the annual reading at $66.4 million for FY2025, 19.21% down from the prior year.
  • Research & Development for Q4 2025 was $18.4 million at Altimmune, up from $15.0 million in the prior quarter.
  • The five-year high for Research & Development was $29.2 million in Q3 2021, with the low at $11.9 million in Q1 2021.
  • Average Research & Development over 5 years is $18.0 million, with a median of $17.8 million recorded in 2023.
  • The sharpest move saw Research & Development surged 125.52% in 2021, then tumbled 30.62% in 2022.
  • Over 5 years, Research & Development stood at $20.2 million in 2021, then dropped by 4.98% to $19.2 million in 2022, then fell by 11.84% to $16.9 million in 2023, then increased by 16.99% to $19.8 million in 2024, then fell by 6.94% to $18.4 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $18.4 million, $15.0 million, and $17.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.